rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 138 139 140 141 142 ... 179 »» | Laatste | Omlaag ↓
  5. [verwijderd] 22 juni 2007 19:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Generex Biotechnology to Make Presentations At the American Diabetes Association's 67th Scientific Sessions
    Friday June 22, 1:23 pm ET


    WORCESTER, Mass., June 22, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making three poster presentations at the American Diabetes Association's 67th Scientific Sessions in Chicago, IL June 22-26, 2007 (http://www.diabetes.org and www.scientificsessions.diabetes.org).

    http://biz.yahoo.com/pz/070622/121836.html
  10. [verwijderd] 25 juni 2007 15:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    HOPPAA!!!!!!

    Generex Biotechnology to Initiate Phase III Clinical Trial of Generex Oral-lyn in 2007 Third Quarter


    2007-06-25 09:10 ET - News Release

    WORCESTER, Mass., June 25, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today at the 67th Scientific Sessions of the American Diabetes Association in Chicago that the Company is preparing to commence a Phase III clinical trial of Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product. The Company has been establishing regulatory and clinical management teams to execute the trials in the United States and abroad. The clinical trial will be undertaken pursuant to a Phase III protocol approved by Health Canada. The United States Food and Drug Administration's review period for the protocol recently lapsed without objection.

    The Company expects to begin dosing patients before the end of the year in centers in the United States, Canada, and Europe.

    The six month trial is expected to include 750 patients with Type 1 diabetes mellitus. Patient enrollment is expected to begin during the third or fourth quarter of calendar year 2007 and expand to several global centers over the course of the study. The primary objective of the study is to compare the efficacy of Generex Oral-lyn(tm) and the RapidMist(tm) Diabetes Management System with that of standard regular injectable human insulin therapy as measured by HbA1c, in patients with Type-1 diabetes mellitus.

    "We are excited to be taking our flagship product into a pivotal Phase III trial, which we believe will represent the final step to achieving approval to market Generex Oral-lyn in North America and Europe," said Anna Gluskin, the Company's President & Chief Executive Officer. "We enter this trial with a great deal of confidence that the results will validate the successful outcomes that patients have experienced in previous clinical trials. This milestone is the culmination of many years of research and development and many successful clinical trials and will set the stage for the global commercialization of Generex Oral-lyn."

    Generex has engaged OSMOS Clinical Research, Inc. (www.osmos.us) of San Francisco, CA to assist the Company with global project management of the Phase III clinical trial. OSMOS has an impressive client roster and over the past few years has provided clinical services for many successful clinical development programs.

    In addition, the Company has engaged Beckloff Associates, Inc. (www.beckloff.com), a Cardinal Health company, to assist the Company with the Generex Oral-lyn Phase III study through the design and implementation of efficient global scientific and regulatory strategies. Beckloff provides a wide range of consulting services required to obtain marketing approval for drugs, biologics, and medical devices for the United States, Canadian, and European markets.

    As previously announced, the Company has engaged Cardinal Health PTS, LLC to produce Generex Oral-lyn for clinical trials. Pursuant to pre-extant supply arrangements, the Company's third-party suppliers have been manufacturing the quantities of the RapidMist(tm) device components (valves, canisters, actuators, dust caps), the insulin, and the formulary excipients that will be required for the Cardinal Health production. In addition, the Company's Regulatory Affairs, Quality Control and R&D personnel have been working with Cardinal Health to prepare and validate the Cardinal Health production processes.


3.572 Posts
Pagina: «« 1 ... 138 139 140 141 142 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.018
AB InBev 2 5.501
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.680
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.703
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.856
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.339
Air France - KLM 1.025 35.047
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.862
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.250
AMG 971 133.370
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.008
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.780
Arcelor Mittal 2.033 320.715
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.741
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.150
ASML 1.766 107.472
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.674
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392